Professor Berent Prakken, MD/PhD - Paediatrician-Immunologist - EUREKA leader

Professor Berent PrakkenBerent Prakken (MD, PhD) is a professor of immunology and pediatrics at the Utrecht Medical Center Utrecht, the Netherlands.  He is also head of research and education of the Wilhelmina Children’s Hospital. Berent Prakken heads a translational research lab that focuses on regulation of inflammation and biomarker development in human inflammatory diseases. Prakken published over 170 articles (H index 37) in international journals, including Nature Medicine, Lancet, PNAS, J Exp Med , Immunity , JCI and Nature Review journals . He and his group received prestigious national and international awards and grants. The Prakken lab hosted a core facility for the Immune Tolerance Network of the NIH, and is an international expertise centre for biomarkers and the luminex technology. Prakken is editor and associate editor of several journals including the Annals of Rheumatic Diseases and the European Journal of Immunology. Berent Prakken was chair of the standing committee of pediatric rheumatology in EULAR, and member of the PRES council and EULAR executive committee. He is member of the steering committee of UCAN and has set up the first international platform for biological studies in arthritis (UCAN-U, www.ucan-u.org). He is coordinator of EUTRAIN, a EU FP7 Marie Curie Integrated Training Network (www.eutrain-network.eu), and partners in various other EU projects. Prakken serves in various national and international research advisory boards and is member of the Dutch National Health Council (‘Gezondheidsraad’). He was vice-chair of the institutional Ethics Review Board.

Berent Prakken’s personal commitment is to collaboration and training & education. Unconventional thinking and crossing traditional boundaries inspired him and his co-founders to set up the Eureka Institute for Translational Medicine (www.eurekainstitute.org)

Professor Norm Rosenblum, MD/PhD - FRCPC - Professor of Paediatrics

Dr. Norman RosenblumDr. Rosenblum is Professor of Pediatrics, Physiology, and Laboratory Medicine and Pathobiology. Dr. Rosenblum is a Pediatric Nephrologist and Senior Scientist in Developmental and Stem Cell Biology at The Hospital for Sick Children. He holds the Canada Research Chair in Developmental Nephrology (2005-2019).  The focus of Dr. Rosenblum’s research is molecular mechanisms that control formation of the normal and malformed mammalian kidney. He is the author of over 100 peer-reviewed papers and chapters on this subject. Dr. Rosenblum is also Associate Dean, Physician Scientist Training, at the University of Toronto.  As Associate Dean, he is Director of the Undergraduate MD/PhD Program and the Postgraduate Clinician Investigator Program, which together consist of over 150 physician scientist trainees.

Dr. Rosenblum is the recipient of the 2004 Aventis Pasteur Research Award, the American Pediatric Society inaugural 2006 Norman J. Siegel New Member Outstanding Science Award, the Society for Pediatric Research 2010 Maureen Andrew Award in Mentoring, and the Kidney Foundation of Canada 2011 Medal for Research Excellence.

Professor Roel Goldschmeding, MD/PhD - Professor of Pathology - Head Honours Programme Master

Professor Roel GoldschmedingRoel Goldschmeding MD, PhD (born 1956), studied Medicine in Groningen and took his PhD at the Central Laboratory of the Red Cross Blood Transfusion Service, now “Sanquin”, University of Amsterdam (1992), where he identified the target antigens of anti-neutrophil cytoplasmic autoantibodies (ANCA), and developed and implemented antigen-specific semi-quantitative assays greatly improving diagnostics and monitoring of patients with small vessel vasculitides. During his residency in Pathology at the AMC in Amsterdam (1993-1997), he began investigating CTGF as a key factor in fibrotic tissue remodeling, and later established CTGF as a critical pathway modifier, biomarker and possible target for therapy in kidney fibrosis. In 1997 he became associate professor of Pathology at the UMC Utrecht, with special responsibilities in pathology of kidney-, immuno-/rheumatological, and (neuro-) endocrine diseases. Since 2010, he is Professor of Translational Pathology in Heart and Kidney at the UMC Utrecht, and continues to serve patient care, pre- and post-graduate teaching, and clinical as well as pre-clinical research in a broad network of national and international collaborators focusing on tissue remodeling in heart and kidney failure, which count among today’s major health care challenges. He is the Head of the Honours Programme Master at Utrecht. Roel Goldschmeding has spent sabbaticals at the University of Erlangen-Nuremberg in Germany (2004), and at FibroGen Inc. (San Francisco, USA), a biotech company involved in the development of anti-CTGF therapy (2007 and 2008-2009).

Dr. Marcel van der Heyden, Principal Investigator - Head of Honours Programme Bachelor

Dr. Marcel van der HeydenMarcel van der Heyden (1966) studied biology at the Utrecht University in the Netherlands. He performed his PhD research on cancer biology, and did two Post-doc positions in the area of developmental biology and Wnt signaling in the late 1990s. In 2000 he moved to the department of Medical Physiology at the University Medical Center Utrecht, The Netherlands and performed research on electrophysiological properties of cardiomyocytes derived from mouse and human stem cells. Currently, he is an associate professor at the department of Medical Physiology. His research focus is on potassium ion channel pharmacology and cardiac arrhythmias. He is associate editor of four peer review physiology journals and is secretary of the Dutch Society of Physiology. He published more than eighty papers in peer reviewed international journals. Finally, he is head of the bachelor Honours Program at the Medical Faculty, a prestigious program for the top 10% of second and third year medical students.

Marjan Oudeman - President of the Executive Board of Utrecht University

Marjan OudemanMarjan Oudeman is the President of the Executive Board of Utrecht University since 2013. She began her career in 1982 in Hoogovens Groep’s legal department as a Corporate Lawyer. Hoogovens merged with British Steel into Corus in 1999 where she later became Chairperson of the Board of Corus Nederland B.V. and fulfilled a variety of executive functions as Corus was incorporated into Tata Steel. Her last held position was Executive Director Corus Strip Products Division. She continued her career at AKZO Nobel in 2010 where she was a member of the Executive Committee from 2011 to 2013. Oudeman is repeatedly named one of the top most influential women according to Management Scope Magazine, was named the ‘Most Influential Businesswoman in 2009’ in the Netherlands by Opzij Magazine and was named the most influential business woman in the Netherlands in 2005 by FEM Business.